IR Notice
CEO IR Newsletter : 2024 AGM Wrap Up
CEO IR NEWSLETTER Driven. For Life.
2024. 03
Announcement
Dear valued shareholders,
This is John Rim from Samsung Biologics.
I would like to take this opportunity to extend my heartfelt
gratitude for your presence at Samsung Biologics' 13th Annual
General Meeting("AGM") and for your unwavering support for our business. Be it resolved that all four proposed agenda items were
approved, and thanks to your active engagement, we wrapped up and closed a successful chapter for 2023 and got 2024 off to a great start.
In particular, I am pleased to announce and welcome Mr. Seoung Hwan Suh who was appointed as a new member to the Board of Directors. Based on his thouough understanding of the global
economy, various industries, and corporate management, as well as a wealth of administrative experience, we expect him to help reinforce independence and transparency of our Board while also contributing to the company's growth administrativeenhancement of shareholder value and rights through more effcient ution and development of management strategies.
Dear shareholders,
in 2024, Samsung Biologics will continue to pusue our vision "to enrich human life with technology and innovation" based on our long-term growth strategy namely the
'three-dimensional-expansion-strategy', which encompasses expansion plans for capacity, portfolio, and geographic footprint.
We will also integrate social responsibility as a global leading
CDMO into the core of our business operations to lead and
establish a better biopharmaceutcal industry. Additionally,
we are committen to flawlessly utiong our business plans to
achieve our annual and long term goals successfully, thereby
enhancing corporate value while also preparing for a sustainable future.
Your continued interest and encouragement going forward is
sincerely appreciated, and we wish you and your family good health and happiness.
Yours Sincerely,
March 15, 2024
President & CEO, Samsung Biologics John Rim
CEO IR Newsletter : 2024 AGM Wrap Up
CEO IR NEWSLETTER Driven. For Life.
2024. 03
Announcement
Dear valued shareholders,
This is John Rim from Samsung Biologics.
I would like to take this opportunity to extend my heartfelt
gratitude for your presence at Samsung Biologics' 13th Annual
General Meeting("AGM") and for your unwavering support for our business. Be it resolved that all four proposed agenda items were
approved, and thanks to your active engagement, we wrapped up and closed a successful chapter for 2023 and got 2024 off to a great start.
In particular, I am pleased to announce and welcome Mr. Seoung Hwan Suh who was appointed as a new member to the Board of Directors. Based on his thouough understanding of the global
economy, various industries, and corporate management, as well as a wealth of administrative experience, we expect him to help reinforce independence and transparency of our Board while also contributing to the company's growth administrativeenhancement of shareholder value and rights through more effcient ution and development of management strategies.
Dear shareholders,
in 2024, Samsung Biologics will continue to pusue our vision "to enrich human life with technology and innovation" based on our long-term growth strategy namely the
'three-dimensional-expansion-strategy', which encompasses expansion plans for capacity, portfolio, and geographic footprint.
We will also integrate social responsibility as a global leading
CDMO into the core of our business operations to lead and
establish a better biopharmaceutcal industry. Additionally,
we are committen to flawlessly utiong our business plans to
achieve our annual and long term goals successfully, thereby
enhancing corporate value while also preparing for a sustainable future.
Your continued interest and encouragement going forward is
sincerely appreciated, and we wish you and your family good health and happiness.
Yours Sincerely,
March 15, 2024
President & CEO, Samsung Biologics John Rim